In vitro evaluation of the efficacy of 8-hydroxyquinoline derivatives for the control of Phaeomoniella chlamydospora, the causative agent of Petri disease in grapevines.

Phaeomoniella 8-hydroxyquinoline antimicrobials fungicides grapevine grapevine trunk diseases quinolines

Journal

Journal of applied microbiology
ISSN: 1365-2672
Titre abrégé: J Appl Microbiol
Pays: England
ID NLM: 9706280

Informations de publication

Date de publication:
04 Oct 2023
Historique:
received: 28 11 2022
revised: 27 09 2023
accepted: 05 10 2023
medline: 2 11 2023
pubmed: 7 10 2023
entrez: 7 10 2023
Statut: ppublish

Résumé

This study evaluates the in vitro efficacy of 8-hydroxyquinoline (8HQ) derivatives in controlling the phytopathogenic fungus Phaeomoniella chlamydospora. The in vitro tests assessed the susceptibility to the minimum inhibitory concentration (MIC), checkerboard assay, mycelial growth (MG) inhibition, and EC50 determination. Among the seven agricultural fungicides tested, tebuconazole (TEB) displayed the lowest MIC, 1.01 µg mL-1, followed by captan (CAP), thiophanate methyl (TM), and mancozeb with MICs of 4.06, 5.46, and 10.62 µg mL-1, respectively. The 8HQ derivatives used in this study were clioquinol and PH 151 (PH) with MICs of 1.09 and 2.02 µg mL-1, respectively. PH associated with TEB and CAP showed synergism and inhibited 95.8% of MG at the highest dose. TEB inhibited 100% of MG at the three highest doses, while associated with PH exhibited the lowest EC50 (0.863 + 0.0381 µg mL-1). We concluded that the 8HQ derivatives tested controlled effectively the P. chlamydospora in vitro. PH associated with CAP and TEB exhibited a synergistic effect. The association between PH and TM was considered indifferent. This study expands the list of active ingredients tested against P. chlamydospora, with the PH 151 and clioquinol derivatives being tested for the first time. The in vitro efficacy and synergistic action with other fungicides suggest a potential use as a grapevine wound protectant. This association makes it possible to reduce doses and increase the potency of both drugs, reducing the risk of resistance development and harm to humans and the environment.

Identifiants

pubmed: 37804172
pii: 7296135
doi: 10.1093/jambio/lxad228
pii:
doi:

Substances chimiques

Fungicides, Industrial 0
Clioquinol 7BHQ856EJ5
Oxyquinoline 5UTX5635HP

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

© The Author(s) 2023. Published by Oxford University Press on behalf of Applied Microbiology International.

Auteurs

Luciana M de Souza (LM)

Programa de Pós-Graduação em Microbiologia Agrícola e do Ambiente, Universidade Federal do Rio Grande do Sul, Porto Alegre/RS. 90035-003, Brazil.
Instituto Federal do Rio Grande do Sul/Campus Bento Gonçalves, Bento Gonçalves/RS. 95700-000, Brazil.

Angelica R Joaquim (AR)

Programa de Pós-Graduação em Ciências Farmacêuticas, Universidade Federal do Rio Grande do Sul, Porto Alegre/RS. 90610-000, Brazil.

Angelo Gava (A)

Programa de Pós-Graduação em Microbiologia Agrícola e do Ambiente, Universidade Federal do Rio Grande do Sul, Porto Alegre/RS. 90035-003, Brazil.

Evandro Ficagna (E)

Instituto Federal do Rio Grande do Sul/Campus Bento Gonçalves, Bento Gonçalves/RS. 95700-000, Brazil.

Marcus A K Almança (MAK)

Instituto Federal do Rio Grande do Sul/Campus Bento Gonçalves, Bento Gonçalves/RS. 95700-000, Brazil.

Saulo F Andrade (SF)

Programa de Pós-Graduação em Microbiologia Agrícola e do Ambiente, Universidade Federal do Rio Grande do Sul, Porto Alegre/RS. 90035-003, Brazil.
Programa de Pós-Graduação em Ciências Farmacêuticas, Universidade Federal do Rio Grande do Sul, Porto Alegre/RS. 90610-000, Brazil.

Alexandre M Fuentefria (AM)

Programa de Pós-Graduação em Microbiologia Agrícola e do Ambiente, Universidade Federal do Rio Grande do Sul, Porto Alegre/RS. 90035-003, Brazil.
Programa de Pós-Graduação em Ciências Farmacêuticas, Universidade Federal do Rio Grande do Sul, Porto Alegre/RS. 90610-000, Brazil.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH